Company Filing History:
Years Active: 2025
Title: Anna Osmukhina: Innovator in Cardiac Treatment
Introduction
Anna Osmukhina is a prominent inventor based in Portland, OR (US). She has made significant contributions to the field of cardiology, particularly in the treatment of hypertrophic cardiomyopathy. Her innovative approaches have the potential to improve patient outcomes and advance medical science.
Latest Patents
Anna holds a patent for "Methods for treating hypertrophic cardiomyopathy." This patent describes treatment methods that include the administration of a cardiac myosin inhibitor, specifically CK-3773274, also known as CK-274 or aficamten. The methods involve titrating the daily dose based on various components of an echocardiogram, allowing for personalized treatment plans. The daily dose may be adjusted based on the echocardiogram results, which can lead to better management of the condition.
Career Highlights
Anna is currently associated with Cytokinetics, Inc., where she continues to work on innovative solutions for cardiac health. Her dedication to research and development has positioned her as a key figure in her field. With her expertise, she is contributing to advancements that could change the landscape of cardiac treatment.
Collaborations
Some of Anna's notable coworkers include Fady Malik and Stuart Kupfer. Their collaboration fosters a dynamic environment for innovation and research, enhancing the potential for groundbreaking discoveries in cardiac treatment.
Conclusion
Anna Osmukhina is a trailblazer in the field of cardiac treatment, with her patent and work at Cytokinetics, Inc. showcasing her commitment to improving patient care. Her contributions are paving the way for future advancements in the treatment of hypertrophic cardiomyopathy.